study question: Are arterial stiffness, carotid intima-media thickness and diastolic dysfunction increased in young women with polycystic ovary syndrome (PCOS) independently of the effects of obesity? summary answer: Insulin resistance and central obesity are associated with subclinical cardiovascular dysfunction in young women, but a diagnosis of PCOS does not appear to confer additional risk at this age.
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder of young women characterized by hyperandrogenism, insulin resistance and glucose intolerance (Dunaif, 1997) . These metabolic disturbances lead to an increased risk of type 2 diabetes (Moran et al., 2010; Morgan et al., 2012) , but their effects on cardiovascular morbidity and mortality are uncertain. A sub-analysis of the Women's Ischemia Syndrome Evaluation (WISE) study showed that post-menopausal women with PCOS had a higher prevalence of multi-vessel cardiovascular disease than controls, and a lower cardiovascular event-free survival than women without features of PCOS (Shaw et al., 2008) . In contrast, our own and other studies have failed to demonstrate an increased incidence of cardiovascular events in pre-or post-menopausal women with PCOS (Wild et al., 2000; Schmidt et al., 2011; Morgan et al., 2012) . Many studies have suggested that measures of cardiovascular risk are increased in young or middle-aged women with PCOS, including endothelial dysfunction (Paradisi et al., 2001) , carotid intima-media thickness (Talbott et al., 2000) , arterial stiffness (Meyer et al., 2005) and myocardial dysfunction (Yarali et al., 2001; Orio et al., 2004) , but it is difficult to establish how much of this risk is due to PCOS per se and how much to obesity, which is common in PCOS and itself associated with greater vascular risk (De Michele et al., 2002) . Recent observations have shown that large artery distensibility was not different between PCOS subjects and healthy controls, but was inversely related to adiposity (Ketel et al., 2010) .
The mechanisms by which obesity contributes to cardiovascular risk are unclear but accumulation of abdominal (visceral) fat appears to carry particular significance since it is an independent risk factor for cardiovascular disease (Abate et al., 1995) and is associated with an increased risk for the development of type 2 diabetes independently of body mass index (BMI) (Boyko et al., 2000) . However, non-obese women with PCOS are also predisposed to glucose intolerance (Legro et al., 1999; Morgan et al., 2012) and might be prone to vascular dysfunction since insulin resistance itself is associated with altered large artery compliance (Giltay et al., 1999) and endothelial function (Cleland et al., 2000) . The inability of insulin to reduce aortic stiffness in insulin-resistant subjects correlates closely with whole-body insulin resistance (Westerbacka et al., 1999) , suggesting that defects in the metabolic action of insulin are accompanied by abnormal vascular function.
In light of these considerations, we sought to undertake a comprehensive assessment of cardiovascular function in a large sample of young women with PCOS compared with healthy volunteers, in order to determine whether cardiovascular risk is increased in young women with PCOS independently of the effects of obesity, and to explore the relationships of arterial stiffness, common carotid intima-media thickness (ccIMT) and myocardial function with regional body composition and insulin sensitivity.
Materials and Methods

Patient selection
Patients with PCOS (n ¼ 84 [69 Caucasian, 7 Asian, 4 Afro-Caribbean, 2 mixed race, 2 Arab]; age 16 -45 years) were identified and recruited from a departmental database or from consecutive patients attending the endocrine clinic at the University Hospital of Wales (2009 Wales ( -2012 . A diagnosis of PCOS was made according to the Rotterdam criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . Congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumours, hyperprolactinemia and thyroid disease were excluded by biochemical testing. We excluded those who were pregnant, breastfeeding and those who had used glucocorticoids, lipid-lowering or glucose-lowering agents, antihypertensives or anti-obesity drugs within 3 months of the study. Of 570 patients considered, 229 were excluded due to a different final diagnosis, co-existing diabetes, hypertension or hypercholesterolaemia, or treatment with metformin, statins or anti-hypertensives. A further 257 were not contactable or declined to take part. Of the final sample of 84 women, 62 had polycystic ovaries on ultrasound, 75 had oligo-/anovulation and 75 had clinical or biochemical hyperandrogenism.
Healthy volunteers (n ¼ 95 [90 Caucasian, 3 Asian, 1 Afro-Caribbean, 1 mixed race]; age 16-45 years) were recruited as controls by advertisement in the local press, among medical students and staff within our institutions. The volunteers had regular menstrual cycles (every 27-32 days). Their healthy status was determined by history, physical examination and hormonal evaluation (testosterone, thyroid function, prolactin and 17-hydroxyprogesterone); to minimize potential for confounding, those with signs of hirsutism or a family history of PCOS were also excluded as were those with a history of known hypertension or diabetes. Healthy volunteers were not taking any lipid-or glucose-lowering agents, antihypertensives or anti-obesity drugs within 3 months of the study. A total of 269 healthy volunteers responded to the advert, but 174 were excluded as they failed to meet the inclusion/exclusion criteria.
Subjects with PCOS, mild oligomenorrhoea or eumenorrhoea were studied in the early follicular phase of their menstrual cycle but no temporal limitations were applied to women with severe oligomenorrhoea or amenorrhoea. In the PCOS group there were 15 current smokers and 12 ex-smokers (32.1%) compared with 11 current smokers and 19 ex-smokers among the healthy volunteers (31.6%). Of the healthy volunteers, 28 (29.5%), were taking a combined oral contraceptive pill compared with 19 (22.6%) subjects with PCOS.
The study was approved by Cardiff and Vale University Health Board Research and Development department, Cardiff University (study sponsors) and the South East Wales Research Ethics committee. All subjects gave written informed consent prior to study commencement.
Assessment of body composition
Subjects attended our Clinical Research Facility at 0800 hours after an overnight fast. Height, weight, waist and hip circumference were measured according to our published protocol (21). Abdominal subcutaneous and visceral fat (VF) areas were measured by X-ray computed tomography (CT) (Hawkeye, GE Medical Systems) on one cross-sectional scan obtained at the level of L4 -L5. Scans were performed with subjects in the supine position using standard acquisition parameters (140 kV, 2.5 mA, 10 mm slice width, 13.6 s rotation time, 256 2 pixel matrix). CT images were segmented into fat and non-fat areas according to our previously published protocol (Watson et al., 2009) .
Arterial measurements
Brachial blood pressure was measured in the left arm (Omron 705IT; Omron Corp., Tokyo, Japan) after 5 min of rest. Estimates of arterial stiffness (augmentation index corrected for a heart rate of 75 bpm , brachial [bPWV] and aortic pulse wave velocity [aPWV] ) were determined by applanation tonometry (AtCor Medical, New South Wales, Australia) in accordance with international recommendations (Van Bortel et al., 2002) . Each of the measurements was performed twice and the average was taken. All measurements of arterial stiffness were performed by a single investigator (R.C.). The intra-observer coefficient of variation was 5% for aPWV. ccIMT of the far artery wall was assessed by ultrasound imaging (Aloka Prosound SSD-5500, 7.5 MHz linear array transducer). Measurements were taken off-line, from a one centimetre segment of the left and right common carotid artery proximal to the bifurcation, using automated tracking and analysis software (Carotid Analyzer, Medical Imaging Applications). The software measures ccIMT at each pixel within the region of interest at every end-diastolic frame ( 140 measurement points). A minimum of five enddiastolic frames were studied and a mean of left-and right-sided values was used in statistical analyses. The intra-observer coefficient of variation was 5% for the right and 6% for the left common carotid artery.
Myocardial function measurements
Systolic and diastolic function were assessed by echocardiography (Vivid 7, GE Medical Systems, Horten, Norway, with a 2.5 MHz transducer and harmonic imaging). Standard echocardiographic measurements and calculations were performed according to the recommendations of the European Association of Echocardiography (Lang et al., 2006) . Images were acquired at passive end-expiration where possible. All measurements were performed during off-line analysis using the EchoPAC PC software version 110.0.0 (GE Healthcare).
Longitudinal systolic function (s') and diastolic function (e ′ , a ′ and e ′ :a ′ ratio) were assessed by pulsed myocardial velocity imaging of the lateral and septal mitral annulus averaged over three consecutive cycles. The e ′ and a ′ are measures of left ventricular myocardial velocity related to passive filling and the component of filling related to atrial contraction, respectively. In a compliant ventricle, the majority of filling occurs passively and e ′ is larger than a ′ . In impaired relaxation, e ′ declines and a ′ increases as atrial contraction contributes more towards diastolic filling. We selected these sensitive echocardiographic measures of function because they are independent predictors of mortality in the general population (Mogelvang et al., 2009) . We expected that insulin resistance and obesity would affect diastolic function (stiffness) and so we used a combined measure of diastolic function (e ′ :a ′ ) to summarize the pathophysiological effects. All echocardiographic and ccIMT measurements were performed by a single investigator blind to subject status (E.R.). The typical intra-observer coefficient of variation for myocardial velocities in our laboratory is 10%.
Biochemical measurements
Fasting blood samples were drawn from the antecubital vein. Serum was prepared by centrifugation of blood at 4000 rpm for 8 min and stored at 2308C prior to analysis. Serum total cholesterol, high density lipoprotein cholesterol (HDL) and triglycerides were assayed using an Aeroset automated analyser [Abbott Diagnostics, Berkshire, UK]; LDL cholesterol (LDL) was calculated using Friedewald's formula. Insulin was measured using an immunometric assay specific for human insulin [Invitron, Monmouth, UK] and glucose was measured using the Aeroset chemistry system [Abbott Diagnostics, Berkshire, UK]. High sensitivity C-reactive protein (hsCRP) was assayed by nephelometry [BN TM II system, Dade Behring, Milton Keynes, UK] and total testosterone was measured by liquid chromatography-tandem mass spectrometry [Quattro TM Premier XE triple quadrupole tandem mass spectrometer, Waters Ltd, Watford, UK]. High molecular weight (HMW) adiponectin was measured by ELISA (EMD Millipore, Billerica, MA, USA). The intra-and inter-assay coefficients of variation were all ,9%. After basal sampling, subjects underwent a standard 75 g oral glucose tolerance test (OGTT). Glucose and insulin were measured at 0, 30, 60, 90 and 120 min. The areas under the curve (AUC) for insulin and glucose were calculated using the trapezoid method. The homeostatic model assessment (HOMA) method was also used to estimate insulin resistance (HOMA-IR) (Matthews et al., 1985) .
Statistical analyses
Comparisons between patients with PCOS and controls, both unadjusted and adjusted, were performed by using linear models when distributions of variables were approximately normally distributed and by using bootstrapping when this was not the case. Relationships with age and BMI were checked for approximate linearity using graphical methods and by examining residuals.
Relationships between fat measures and arterial stiffness parameters were also estimated using linear modelling. Fat measures were first converted into Z-scores to facilitate comparison between models; a regression coefficient associated with a fat measure can then be interpreted as the effect on the outcome of a change of one standard deviation of the fat measure. Models were adjusted for age, central pulse pressure and, where there was evidence that body size was a confounder, for height. Interaction terms between PCOS status and the explanatory factors were included in the models to test if the relationships varied between PCOS subjects and controls.
The planned sample size was 80 in each group. This would give 80% power for detecting a difference of 0.45 m/s in aortic PWV or one of 0.25 in e ′ :a ′ , which we considered clinically significant (Cruickshank et al., 2002; Mogelvang et al., 2009) . The likely power for the regression analyses was harder to estimate without detailed knowledge of the relationships but we estimated there to be 80% power for detecting partial correlation coefficients of around 0.25. Table I shows the clinical and metabolic characteristics of the PCOS and healthy volunteer groups. Women with PCOS were significantly heavier and younger on average than the healthy volunteers. As expected, PCOS subjects had higher testosterone, HOMA-IR and glucose/insulin responses to glucose challenge, compared with healthy volunteers and adjusting for age and BMI, indicating reduced insulin sensitivity. Subjects with PCOS also had higher triglycerides and hsCRP but after adjustment for the differences in age and BMI, these were no longer significant. HMW adiponectin, which did not differ between subjects with PCOS and controls in the unadjusted analysis, was significantly higher in the PCOS group after adjustment. Table II shows estimates of arterial stiffness, ccIMT, and myocardial structure and function in the two groups. In the unadjusted analyses, subjects with PCOS had higher resting heart rate, fractional shortening, and peripheral and central diastolic blood pressure. These differences were no longer significant after adjustment for the differences in age and BMI.
Results
Comparison of metabolic and cardiovascular risks
For subsequent analyses, we focused our attention on three principal cardiovascular risk measures: aPWV and ccIMT, as these measures have the greatest validity as predictors of cardiovascular events in the general population (Willum-Hansen et al., 2006; Lorenz et al., 2007) , and the ratio of peak early to late diastolic mitral annulus velocity (e ′ :a ′ ), as this measure of diastolic function is less sensitive to changes in preload (Sohn et al., 1997) , an important consideration in our population because of the potential influence of obesity.
Associations of body composition and insulin resistance with cardiovascular measures
To explore the effects of body composition on cardiovascular function in women with PCOS, we initially compared aPWV, ccIMT and e ′ :a ′ according to quartile of BMI. After adjustment for age and central pulse pressure, PCOS subjects in the lowest three quartiles had significantly lower aPWV than the most obese quartile. For e ′ :a ′ , values were significantly higher in the two lowest quartiles compared with the most obese, whereas for ccIMT there were no significant differences between quartiles (Table III) . To further define the relationships between obesity, insulin resistance and cardiovascular function, we subsequently undertook a multivariable analysis in which we controlled for the potential confounders of age, height, central pulse pressure and LDL cholesterol. All measures of adiposity (BMI, waist circumference, weight, subcutaneous fat area, VF area) gave similar relationships with e ′ :a ′ , aPWV and ccIMT. Insulin resistance was measured by HOMA-IR. Table IV shows the standardized regression coefficients and percentage variation explained by logVF area, BMI, HOMA-IR and insulin area under the curve (IAUC), adjusted for age, height, central pulse pressure and LDL cholesterol. All the adiposity measures were strongly associated with both e ′ :a ′ and aPWV; and the interaction terms were not significant, suggesting that the relationships between the cardiovascular risk factors and the explanatory variables were similar in PCOS and control subjects. For ccIMT, there were no significant associations with VF, BMI or HOMA-IR; insulin AUC was related to ccIMT in the control subjects but not in those with PCOS. In order to explore whether adiposity and insulin resistance affected cardiovascular function independently of one another, we further adjusted our results on insulin sensitivity for logVF (Table V) of HOMA-IR and e ′ :a ′ . Since testosterone and adiponectin levels were higher in the PCOS group, we explored these as potential factors which might protect PCOS patients from adverse cardiovascular outcomes. However, relationships between testosterone and adiponectin and each of aPWV, e ′ :a ′ and ccIMT were generally weak and models with interactions, to allow for different relationships in the PCOS and control groups, explained relatively little of the overall variation in the cardiovascular outcome measures.
Discussion
Our study demonstrates that central arterial stiffness and diastolic dysfunction are not increased in young women with PCOS, after adjustment for age and BMI, whereas they are associated with insulin resistance and abdominal obesity. In other studies of young women with PCOS, arterial stiffness has been increased (Meyer et similar to controls (Muneyyirci-Delale et al., 2007; Ketel et al., 2010) . Discordant findings may reflect limited numbers of subjects, failure to adjust fully for influences of obesity, or the estimation of stiffness in a single arterial territory. Previous studies have assessed adiposity using simple anthropometric measures alone (Meyer et al., 2005; Muneyyirci-Delale et al., 2007; Soares et al., 2008; Trakakis et al., 2008; Ketel et al., 2010) whereas we incorporated CT as a more accurate and precise measure of regional fat distribution. This may be important because a higher BMI may reflect a greater lean mass as well as increased fat. We measured arterial stiffness in elastic (aortic) as well as muscular (brachial) arterial territories and incorporated aPWV as a key outcome measure, which is known to independently predict cardiovascular mortality in the general population (Willum-Hansen et al., 2006) . We did not find any evidence of increased arterial stiffness in our population of women with PCOS compared with healthy volunteers, either in unadjusted analyses or after adjustment for age and BMI. This is in agreement with the findings of both Muneyyirci-Delale et al (Muneyyirci-Delale et al., 2007) , who found no relationship between PCOS and arterial stiffness after adjustment for BMI, and Ketel et al (Ketel et al., 2010) . They also found that central obesity (as determined by measurement of waist circumference), but not PCOS, was associated with increased arterial stiffness. Similarly, we found that even after adjustment for age, height, central pulse pressure and LDL cholesterol, aPWV correlated significantly with measures of obesity, with the strongest relationship occurring for VF area. Measures of insulin resistance (HOMA-IR and insulin AUC) were also associated with aPWV independently of VF area, suggesting that VF and insulin resistance are, at least in part, influencing arterial compliance by separate mechanisms. Hyperinsulinemia has been shown to promote smooth muscle cell growth, endothelial dysfunction, oxidative stress and activation of the sympathetic nervous system (Stehouwer et al., 2008) , which could all contribute to greater arterial stiffness.
Several studies have demonstrated increased carotid IMT in young PCOS subjects, when controlled for age and BMI (Talbott et al., 2000; Orio et al., 2004; Carmina et al., 2006; Cascella et al., 2008) , but these relationships are not always consistent (Costa et al., 2008; Soares et al., 2008) . A recent systematic review and meta-analysis, which considered the confounding effects of age and obesity, concluded that those with PCOS have values 0.08 mm greater than matched controls (Meyer et al., 2012 ). An increase of 0.10 mm predicts a 15% increase in the risk of myocardial infarction and an 18% increase in the risk of stroke (Lorenz et al., 2007) . Interestingly, we did not find evidence of increased ccIMT in our PCOS population compared with controls, nor evidence in PCOS subjects for an association of ccIMT with either insulin resistance or obesity. Heterogeneity in the results may be related to differences in PCOS phenotype between studies; we used the Rotterdam criteria, which permits a diagnosis of PCOS without biochemical evidence of hyperandrogenism. In addition, our subjects were young and metabolic alterations may not result in measurable ccIMT changes until middle-age. Our results are in agreement with those of Talbott et al. (2000) , who reported a mean testosterone of 1.6 nmol/l in PCOS subjects and also failed to detect a significant cIMT difference in subjects younger than 45 years. In comparison, those studies reporting increased carotid IMT in PCOS subjects published mean testosterone values of 2.2-2.8 nmol/l (Orio et al., 2004; Carmina et al., 2006; Cascella et al., 2008) , albeit using testosterone assays that are less specific than the mass spectrometry method which we used.
It has been unclear whether subclinical left ventricular dysfunction is a feature of patients with PCOS and if so, whether this is linked to obesity, insulin resistance, hyperandrogenism or an alternative mechanism. Some studies have reported impaired diastolic function in PCOS subjects compared with age-and BMI-matched controls (Yarali et al., 2001; Orio et al., 2004) , while others have failed to demonstrate any significant difference (Tekin et al., 2009) . Discrepant results may be related, in part, to the lack of sensitivity of traditional left ventricular echocardiographic measures. We assessed myocardial function using myocardial velocity imaging. Kosmala et al. (2008) reported impaired systolic and diastolic function associated with insulin resistance in young obese women when myocardial strain and strain rate were analysed; PCOS did not affect left ventricular function but BMI and fasting insulin were independent correlates of diastolic function. In both respects, our findings are in agreement but we additionally included lean subjects, finding no evidence of an influence of PCOS status on the e ′ :a ′ ratio.
There are several potential mechanisms by which obesity may impair diastolic function. Obesity results in increased blood volume and blood pressure which can lead to compensatory hypertrophy. However, the inverse relationship between obesity and e ′ :a ′ remained significant even after adjustment for central pulse pressure; hence other mechanisms may also be in operation. Hyperinsulinemia, which is common in obesity, may also contribute to hypertrophy through myocyte growth and interstitial fibrosis. Our findings also raise the possibility that young women with PCOS may be afforded some cardio-protection from factors related to the syndrome, although testosterone and HMW adiponectin were not significantly related to the measures of cardiovascular function we assessed. Our study has a number of limitations. Firstly, we studied fairly young women with PCOS so we cannot necessarily extrapolate our findings to older patients with this syndrome. Secondly we did not match our case and control populations a priori for age and BMI, although we adjusted very carefully for the influences of these variables on our cardiovascular outcome measures. Thirdly, because of the cross-sectional design, we cannot discount the possibility that the associations we observed between fat distribution, hyperinsulinemia and cardiovascular risk measures are mediated by an unmeasured common underlying factor. Fourthly, biochemical hyperandrogenism was based solely on measurement of total testosterone. Fifthly, selection bias may also have influenced our findings, either by recruitment of PCOS subjects who were healthier than non-enrolled PCOS women (bias towards the null) or a 'healthy worker' effect (bias away from the null) whereby some of our volunteers were selected from medical staff and students at our institution. Finally, our study may not fully exclude an association between PCOS and arterial stiffness or myocardial function because of the sample size. However, this is one of the largest studies of its kind to have been conducted in this population, suggesting that any effects of PCOS on these measures of cardiovascular function independent of obesity, if present, are likely to be small.
We believe that our study is the first to comprehensively assess the relationships between ccIMT, arterial stiffness, myocardial function, metabolic abnormalities and regional fat distribution in PCOS subjects. Our findings suggest that both central adiposity and insulin resistance contribute to arterial stiffness and impaired diastolic function, but that PCOS status does not confer additional risk. This extends our understanding of cardiovascular risk in young women with PCOS, but further studies are needed to explore the mechanisms involved and establish whether young women with PCOS are afforded some protection from cardiovascular dysfunction by a factor related to the syndrome. In the meantime, our results support the view that central obesity represents the greatest modifiable risk factor for cardiovascular disease in young women with PCOS and that lifestyle measures which target weight reduction are critical.
